Medicover S.R.L.
- Address
- lock Available on a paid plan
Neoplasms – Lung Cancer Research
The oncology department at Medicover S.R.L. is dedicated to advancing treatment for non‑small cell lung cancer, exploring innovative immunotherapy combinations and novel agents to improve survival outcomes.
- Immunotherapy plus chemotherapy regimens
- Adjuvant vaccine strategies alongside checkpoint inhibitors
- Maintenance therapy optimization
- Comparative effectiveness of emerging monoclonal antibodies
- Real‑world data on first‑line treatment pathways
Ongoing studies involve a multidisciplinary team of seven investigators and aim to bring new therapeutic options to patients with advanced disease while ensuring rigorous safety monitoring.
Hemic and Lymphatic Diseases – Thrombosis Prevention
Research at the site also targets cancer‑associated thrombosis, evaluating strategies to prevent clot formation in patients receiving oncology therapies.
- Prophylactic anticoagulant regimens for solid‑tumor patients
- Assessment of bleeding risk alongside thrombosis prevention
- Integration of anti‑thrombotic agents with standard cancer treatment
- Biomarker‑driven selection of patients for prophylaxis
These trials seek to balance efficacy and safety, offering insights that could reduce life‑threatening events while patients undergo cancer therapy.
Analytical & Diagnostic Techniques – Biomarker Evaluation
The department leverages advanced diagnostic platforms to refine patient selection and monitor response in lung cancer studies.
- Validation of PD‑L1 expression as a predictive marker
- High‑resolution imaging for tumor burden assessment
- Companion diagnostic development for novel agents
- Integration of real‑time data analytics in trial conduct
By coupling cutting‑edge equipment with clinical expertise, the site aims to enhance the precision of therapeutic decisions.
Cardiovascular Disease Insights in Oncology
While the primary focus is oncology, the team investigates the cardiovascular implications of cancer treatments, especially in relation to clotting disorders.
- Cardiovascular risk assessment in patients receiving immunotherapy
- Monitoring cardiac safety alongside anti‑thrombotic therapy
- Strategies to mitigate treatment‑related vascular events
- Collaborative care models integrating cardiology and oncology
This interdisciplinary approach supports comprehensive patient care, addressing both tumor control and heart health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Merck Sharp & Dohme LLC2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC4trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medicover S.R.L.
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE | Incyte Corp. | Phase II | Not Recruiting | Nov 2023 | Feb 2026 |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 6 | Unknown | 2018-03-21 | 2025-09-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.